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Background: Emesis and nausea are side effects induced by chemotherapy. These effects lead to enormous stress
and strain on cancer patients. Further consequences may include restrictions in quality of life, cachexia or therapy
avoidance. Evidence suggests that cancer patients develop the side effects of nausea and vomiting in anticipation
of chemotherapy. Contextual cues such as smell, sounds or even the sight of the clinic may evoke anticipatory
nausea and vomiting prior to infusion. Anticipatory nausea and vomiting are problems that cannot be solved by
administration of antiemetica alone.
The purpose of the proposed randomized placebo-controlled trial is to use an overshadowing technique to prevent
anticipatory nausea and vomiting and to decrease the intensity and duration of post-treatment nausea and
vomiting. Furthermore, the effect on anxiety, adherence and quality of life will be evaluated.
Methods/Design: Fifty-two pediatric cancer patients will be evenly assigned to two groups: an experimental group
and a control group. The participants, hospital staff and data analysts will be kept blinded towards group allocation.
The experimental group will receive during three chemotherapy cycles a salient piece of candy prior to every
infusion, whereas the control group will receive flavorless placebo tablets.
Discussion: If an effectiveness of the overshadowing technique is proven, implementation of this treatment into
the hospitals’ daily routine will follow. The use of this efficient and economic procedure should aid a reduced need
for antiemetics.
Trial registration: Current Controlled Trials ISRCTN30242271Background
Around 1,800 children (under 15 years old) per year de-
velop cancer in Germany [1]. The chances of surviving
childhood cancer have increased considerably in the past
30 years due to differentiated diagnostic and develop-
ments in the therapy regimes. Today 83% of all pediatric
cancer patients survive the first 5 years after diagnosis,
an increase from 67% in the 1980s. A reasonable propor-
tion of this development can be attributed to progress in
cytostatics. However, the well-known side effects have
remained. The typical side effects are nausea and* Correspondence: f.geiger@uksh.de
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distribution, and reproduction in any mediumvomiting. Experiences of nausea and vomiting can lead to
anxiety, restrictions in quality of life and reduced adher-
ence to therapy. In the proposed randomized controlled
trial the effectiveness of an intervention technique called
overshadowing on chemotherapy-related nausea and
vomiting will be investigated. Furthermore, the impact on
anxiety, adherence and quality of life will be studied. The
following sections describe the conceptualities.
Emetogenity of cytostatics
Aside from the desired effect of tumor reduction, cyto-
statics affect a number of organ systems. Amongst other
systems, cytostatics stimulate the area postrema, a
circumventricular organ that lies outside the blood–
brain barrier, stimulation of which can lead to vomiting
[2]. Nausea and vomiting are considered by patients to
be the most burdening adverse reactions and the mostCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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nausea and vomiting raise the risk of developing Mallory–
Weiss syndrome. Furthermore, prolonged nausea and
vomiting could produce exsiccosis, cause electrolyte im-
balance and lead to a high level of weight loss [3].
The frequency of chemotherapy-induced emesis de-
pends primarily on the emetogenic potential of the
cytostatics. The Multinational Association of Supportive
Care in Cancer (MASCC) classifies the cytostatics in
four emetic risk groups. A high-level agent produces
emesis in nearly all patients (>90%), a moderate-level
risk in 30 to 90% of patients, a low-level risk in 10 to
30% of patients and the minimal level tends to show risk
in <10% of patients [4]. Table 1 presents the emetic risk
groups of cytostatics.
Post-treatment nausea and emesis
Chemotherapy-induced nausea and/or emesis are com-
monly classified as acute, delayed, anticipatory, break-
through or refractory [5]. Acute onset usually occurs
within a few minutes to 1 or 2 hours after infusion and re-
solves within the first 24 hours. Delayed onset emesis be-
gins or persists more than 24 hours after chemotherapy
treatment. Anticipatory nausea and emesis occurs before
patients receive their chemotherapy administration. Break-
through emesis occurs despite prophylactic treatment and
requires rescue antiemetics. Refractory emesis arises dur-
ing subsequent treatment cycles when antiemetic prophy-
laxis and rescues have failed in earlier cycles.
Chemotherapy-induced nausea and vomiting differs
from that usually experienced – it lasts longer, its degree
of severity varies from treatment to treatment and there
is a greater variability in patient reaction. For example,
anxiety, personality and environment seem to play a key
role. Factors that increase the risk of nausea and emesis
beside pharmacological (dosage, agent, duration) are age,
gender and expectation of these adverse effects [6].Table 1 Emetic risk groups according to MASCC
Risk Cytostatics
High Cisplatin, mechlorethamine, streptozocin, cyclopho
Oral: Hexamethylmelamine, procarbazine
Moderate Oxaliplatin, cytarabine >1,000 mg/m2, carboplatin,
doxorubicin, daunorubicin, epirubicin, idarubicin, i
Oral: Cyclophosphamide, temozolomide, vinorelbi
Low Paclitaxel, docetaxel, mitoxantrone, topotecan, eto
temsirolimus, ixabepilone, mitomycin, gemcitabine
trastuzumab, catumaxomab, panitumumab
Oral: Capecitabine, tegafur uracil, etoposide, suniti
Minimal Bleomycin, busulfan, cladribine, fludarabine, vinbla
vinorelbine, bevacizumab
Oral: chlorambucil, hydroxyurea, melphalan, metho
gefitinib, sorafenib, erlotinibInitiation and coordination of the emetic process is
the responsibility of the vomiting center, a structure lo-
cated in the lateral reticular formation of the medulla.
Afferent input from several sources, including the higher
brain stem and cortical structures, are capable of initiat-
ing the emetic process [7].
Antiemetics
The MASCC published guidelines for the use of anti-
emetics [4]. For adult patients with high emetic risk from
chemotherapy, a combination of a 5-HT3 receptor antag-
onist, dexamethasone, and aprepitant is recommended
prior to chemotherapy.
For patients who receive moderate emetic-risk chemo-
therapy, not including a combination of anthracycline
plus cyclophosphamide, palonosetron plus dexamethasone
is recommended for prophylaxis of acute nausea and
vomiting. Patients who receive moderately emetic chemo-
therapy known to be associated with a significant incidence
of delayed nausea and vomiting should receive antiemetic
prophylaxis for delayed emesis. A single antiemetic agent
such as dexamethasone, a 5-HT3 receptor antagonist, or a
dopamine receptor antagonist, such as metoclopramide, is
suggested for prophylaxis in patients receiving agents of
low emetic risk. No antiemetic should be administered for
the prevention of delayed emesis induced by low or min-
imally emetic chemotherapy. The MASCC describes that
the best approach for anticipatory emesis is the best pos-
sible control of acute and delayed emesis. The guidelines
for the chemotherapy-induced prevention of nausea and
vomiting for high and moderate risk in children states that
all patients should receive antiemetic prophylaxis with a
combination of a 5-HT3 receptor antagonist and dexa-
methasone. There are currently no appropriate studies
available for the prevention of delayed anticipatory nausea
and vomiting (ANV) or for the prevention of nausea and
vomiting following chemotherapy of minimal and lowsphamide >1,500 mg/m2, carmustine, dacarbazin
ifosfamide, cyclophosphamide <1,500 mg/m2, azacitidine, alemtuzumab,
rinotecan, bendamustine, clofarabine
ne, imatinib
poside, pemetrexed, methotrexate, doxorubicin HCl liposome injection,
, cytarabine <1,000 mg/m2, 5-fluorouracil, bortezomib, cetuximab,
nib, fludarabine, everolimus, lapatinib, lenalidomide, thalidomide
stine, vincristine
trexate, 6-thioguanine
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available. The MASCC suggests that children should be
treated in a manner similar to that of adults receiving
chemotherapy with appropriate doses. This limited level of
standardization may lead to widely varying antiemetic
strategies in different centers. However, the MASCC rec-
ommendations are similar to, for example, those given in
the protocol for one of the largest therapy-optimizing stud-
ies worldwide [8], for acute lymphoblastic leukemia.
Ihbe-Heffinger and colleagues observed that the ma-
jority of their adult patients (64.4%) experienced nausea
and emesis, although they took prophylactic medication
[9]. More patients experienced delayed than acute nau-
sea and emesis (60.7% vs. 32.8%), and more patients
reported nausea than vomiting (62.5% vs. 26%). The au-
thors concluded that antiemetic medications could con-
trol acute rather than delay emesis and should effect a
reduction in the frequency of vomiting but not in epi-
sodes of nausea.
Anticipatory nausea and emesis
As already mentioned, many cancer patients not only
experience the side effects of nausea and emesis after
chemotherapeutic drug infusion, but also prior to treat-
ment [10]. These symptoms are known as ANV. The
incidence ranges from 18 to 57% and nausea is more
common than vomiting [5]. The reported rates vary
widely among studies. Morrow and colleagues found in
their meta-analysis of 35 studies an average prevalence
of 29% for adult and pediatric patients [11]. Despite
modern antiemetic treatment, ANV still occurs in 25 to
30% of cases [12].
The etiology of ANV can be explained by classical
conditioning established by Pavlov (1849 to 1936). Dur-
ing conditioning an organism learns to associate an ini-
tial neutral stimulus (the conditioned stimulus) with a
biologically relevant stimulus (the unconditioned stimu-
lus). By pairing a conditioned stimulus with an uncondi-
tioned stimulus in the acquisition phase, the conditioned
stimulus comes to evoke a conditioned response that is
commonly similar to the response elicited by the uncon-
ditioned stimulus [13].
Accordingly, contextual stimuli of the clinic environ-
ment, such as the smell, sounds and sight of the build-
ing, function as the conditioned stimulus that becomes
associated with the unconditioned stimulus of chemo-
therapy treatment. Following one or more contingent
pairings (chemotherapy infusions), the patient may de-
velop the conditioned response of nausea and/or vomiting
even before the next treatment just by seeing the infusion,
meeting the same clinician or already while re-entering
the clinic [14].
As shown by Hickok and colleagues, the development of
ANV coheres with the emetogenicity of the chemotherapydrug [15]. Beyond that, Tyc and colleagues showed that
occurrence of ANV is positively correlated with severity of
vomiting (intensity, frequency, duration) and number of
chemotherapy cycles (conditioning trials) [16]. ANV is fur-
ther inversely correlated with patient age, according to
Morrow [17].
ANV is also seen in animal models. Limebeer and col-
leagues observe that, although rats do not vomit, they
display a distinctive gaping reaction when exposed to a
toxin-paired flavored solution [14]. After several pairings
the contextual cues elicit a conditioned state of nausea
in rats.Quality of life
Quality of life is defined as a health-related multidimen-
sional construct that includes physical, emotional, men-
tal, social and behavioral components of well-being and
functioning from the viewpoint of patients respective to
observers [18].
Calaminus and colleagues found that patients who sur-
vived childhood cancer estimate their quality of life to
be as good as that of healthy children of the same age
[19]. However, the various aspects of quality of life are
judged differently among the diverse oncological do-
mains. For example, children with solid tumors show
less impairment than children with leukemia; one could
therefore suggest that a diagnosis at young age and a
longer period of being dependent on family support, iso-
lation from peer groups and delayed independence may
be reflected by this result [19].
Previous studies estimate an influence of nausea and
emesis on cancer patients’ quality of life [20,21].
As shown by Akechi and colleagues, the presence of
anticipatory nausea was significantly affecting most do-
mains of patients’ quality of life [22]. This influence main-
tains when controlling for age, sex, performance status,
and psychological distress.Anxiety
State anxiety (as opposed to trait anxiety) is defined as
an emotional process signed through arousal, worries,
nervousness, inner restlessness and fear of future events.
State anxiety varies in intensity, time and situation [23].
Anxiety is the result of threats that are perceived to be
uncontrollable or unavoidable [24].
State anxiety is associated with incidence and severity
of post-treatment vomiting, and varies inversely with the
emetic potential of the chemotherapy regimen [7]. This
counterintuitive finding might be explained by psycho-
logical factors being relevant in the experience of post-
treatment vomiting for regimens of low to moderate
emetic potential while their impact might be reduced or
minimal for regimens with high emetic potential.
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facilitates classical conditioning of anticipatory responses
[17]. A review by Andrykowski comprising 12 studies
showed mixed results [25]. The relationship between
anxiety and ANV seems unclear.
A study with pediatric cancer patients found no sig-
nificant differences in state anxiety scores between pa-
tients, whether or not they experience ANV [26].
Compliance/adherence
Compliance was previously defined as the willingness to
follow medical advice. Understanding of the patient’s
role, however, has changed in recent decades. As a con-
sequence the term adherence is increasingly used instead
of compliance. Adherence expresses an active patient
role with the aim to create a cooperation based on
agreement between physicians and patients that should
lead to maintenance in therapy regimens [27]. In the lit-
erature, compliance is still synonymously used for adher-
ence. Reasons for nonadherent behavior are shown in
Table 2.
Predictors for adherent behavior from pediatric cancer
patients mentioned in the review by Tebbi are the mode
of application, satisfaction with medical supply, inner be-
lief of control and age [28]. Adolescents often showed
nonadherent behavior. Factors such as gender, parental
income or family status had no influence on adherence.
Adherence is important for treatment success. A low
degree of adherence is found to lead to increased mor-
tality [27].
Overshadowing
The phenomenon of overshadowing was first observed
by Pavlov [29]. When two or more stimuli are present,Table 2 Reasons for nonadherent behavior of patients
[45]
Patient-related factors Therapy-related factors
• Low level of suffering • Complexity of regimen
• Anxiety that therapy harms • Side effects
• Anxiety that medication leads to
nausea/vomiting, and so forth
• Long-term therapy
• Syringe phobia
• Negative experiences related to
clinic or doctor
• Laziness, restrictions in intelligence
or memory
Doctor–patient relationship Institution
• Insufficient education and
information
• Longer waiting times
• Dissatisfaction • Insufficiently structured
processes
• Long consultation intervalthe more salient one produces a stronger response than
the other. The presence of the more salient element is
commonly found to restrict the acquisition of associative
strength by the less salient element [30].
Pavlov explained it as follows: ‘The effect of the com-
pound stimulus is found nearly always to be equal to that
of the stronger component used singly, the weaker stimu-
lus appearing therefore to be completely overshadowed by
the stronger one’ [29].
Transferring the overshadowing paradigm to chemo-
therapy processes, a salient stimulus presented during
drug infusion may overshadow the effects of the less sa-
lient one (the doctor’s white coat). The conditioned re-
sponse elicited by the less salient stimuli is weakened
through the overshadowing element. This weakening
prevents the development of ANV [10]. According to
Garcia and Koelling, tastes become more associated with
stimuli causing nausea and vomiting [31]; they are more
salient than other sensational perceived stimuli.
Examination of the psychological, medical and nursing
literature in PubMed for the overshadowing procedure,
also known as the scapegoat technique from classical
conditioning, revealed a total number of 124 findings
(see search strategy in Table 3). The majority of studies
attend to foundational research of overshadowing; for
example, the involved brain functions during associative
learning.
A limited search focusing on cancer leads to four arti-
cles about the scapegoat effect on food aversion from
cancer patients [32-35], while two articles consider the
overshadowing effect on conditioned nausea [10,36]. Of
these, just one describes an investigation among pediatric
cancer patients [34]. Screening of the reference lists of
these articles did not add any previously unconsidered
publications.
Broberg and Bernstein used a scapegoat technique to
prevent food aversion in children undergoing chemo-
therapy [34]. Patients received candy (coconut and root
beer Lifesavers) between the consumption of a meal and
administration of chemotherapy. Children who received
the candy, which served as a scapegoat, were twice as
likely to eat some portion of a future test meal.
Stockhorst and colleagues investigated 16 adult cancer
patients with an overshadowing protocol using salient
drinks to prevent anticipatory nausea and emesis [10].
The experimental group (n = 8) received salient drinks
before administration of drug infusions through two
cycles of chemotherapy, while the control group received
water. In the third cycle of chemotherapy all patients
received water. Patients receiving an overshadowing
treatment did not develop anticipatory nausea, whereas
two patients of the control group did. Furthermore,
overshadowing tended to modify the occurrence of post-
treatment nausea: it occurred later and was of shorter
Table 3 Search terms and results of the systematic literature review
Number Queries Result
#14 Search (#7) AND #3 Limits: Randomized Controlled Trial, Cancer 0
#13 Search (#7) AND #3 Limits: Cancer, Young Adult: 19–24 years 0
#12 Search (#7) AND #3 Limits: Cancer, All Child: 0–18 years 0
#11 Search (#7) AND #3 Limits: Cancer 2
#10 Search (#7) AND #3 4
#9 Search (#1) AND #2 Limits: Cancer, All Child: 0–18 years 1
#8 Search (#1) AND #2 Limits: Cancer 6
#7 Search (#1) AND #2 124
#6 Search #4 Limits: Humans, Cancer, All Child: 0–18 years 2
#5 Search #4 Limits: Humans, Cancer 33
#4 Search #1 Limits: Humans 263
#3 Search ((((((anticipatory nausea) OR anticipatory emesis) OR anticipatory vomiting) OR
chemotherapy-related nausea) OR chemotherapy-related vomiting)) OR chemotherapy-related emesis
531
#2 Search (((classical conditioning) OR pavlovian conditioning) OR pawlowian conditioning) OR conditioned 84,626
#1 Search (overshadowing) OR scapegoat 463
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cause of a quite small sample size; they only suggest
tendencies.
In a pilot study at our medical center, Görges adapted
the study design of Stockhorst and colleagues [10] for
the pediatric setting (n = 30), where overshadowing
proved to be effective [37]. No patient of the over-
shadowing group (n = 15) developed anticipatory nau-
sea, compared with 13 patients of the control group.
Furthermore, overshadowing reduced the occurrence of
concomitant symptoms such as anxiety, nonadherent
behavior and affected well-being. Overshadowing also
seemed to decrease the intensity of post-treatment nau-
sea. However, the partially insufficient feasibility of the
used intervention technique led to problems of recruit-
ment. This problem may have biased the results towards
an overestimation of the intervention effect. Such threats
of validity have to be avoided in the present study. Add-
itionally, reducing the complexity of the intervention in-
creases the chances of implementation into daily clinical
routine.
Aims of the study
The aims of the present study were to verify the effect of
an optimized overshadowing technique on ANV (primary
endpoints), and to further investigate the intervention ef-
fect on post-treatment nausea and vomiting (secondary
endpoints). The subgoals were to investigate the over-
shadowing effect on patients’ quality of life, state anxiety
and adherence; to survey the relation between prevalence
of post-treatment and ANV; and to determine the applic-
ability of the overshadowing treatment in the hospital’s
daily routine.Methods/Design
Ethical approval
The study protocol was approved by the ethics commit-
tee of the Christian-Albrechts-University, Medical Fac-
ulty, Kiel, Germany (6 March 2012, reference number A
168/11).
Participants and their parents shall receive written in-
formation and are required to give their written consent
prior to participation.
Participants
Newly diagnosed pediatric patients with an oncological
disease shall be included in the Kiel University clinic.
These children, adolescents and young adults must also
meet further inclusion criteria: German speaking, over
the age of 4 years, and receiving chemotherapy. To guar-
antee a proper acquisition phase of overshadowing, the
children should run through at least three chemotherapy
cycles. An interval of 7 days between each chemotherapy
cycle is important to differentiate between post-treatment
and ANV. Children with brain or gastrointestinal tract
cancer will be excluded to eliminate an organic cause of
nausea and vomiting. Other exclusion criteria include
mental restrictions, recurrent cancer, and received radio-
therapy. Finally, pediatric patients should not have experi-
enced treatment-related nausea or vomiting before.
Sample size calculation
The calculation of the required sample size is oriented
towards the demands of the first study question, which
addresses the effect of overshadowing on ANV (primary
endpoints). The effect sizes that were achieved in our
pilot study for reduction of ANV are to be judged as
Geiger and Wolfgram Trials 2013, 14:103 Page 6 of 9
http://www.trialsjournal.com/content/14/1/103very large in view of statistical conventions (effect sizes
in t tests were d = 2.5 (nausea) and d = 1.4 (vomiting)).
For the present study, a more conservative effect size of
f = 0.4 in analysis of covariance (see below) is assumed.
Aiming at a statistical power of 0.80, a total sample size
of n = 52 is needed (two-sided α = 0.05).
Study design
The study is a monocenter randomized controlled trial
comparing groups of pediatric cancer patients undergo-
ing an overshadowing treatment during chemotherapy
or receiving a placebo treatment. Figure 1 shows the
study design.
Different diagnoses require different cytostatics. Drugs,
in turn, influence the probability of usage and the type
of antiemetics. Block randomization will therefore be
conducted within each diagnosis (that is, within the group
of patients suffering from acute lymphoblastic leukemia or
those suffering from Ewing’s sarcoma, and so forth).
According to the recommendations of Altman and Bland
[38], separate block randomization lists for each stratum
will be used. This process is carried out by an independentFigure 1 Study design and flow of participants.third person not involved in data collection, analysis or
medical care.
Participants, medical staff and data analysts will be
kept blinded towards allocation. While blinding of med-
ical staff and data analysts is easily realized, participants
may notice if they get candy with a salient taste (experi-
mental group) or without (control group). However, as
the study information leaflets do not refer to taste in
particular but to the effect of melting something in one’s
mouth, they are not able to conclude their group alloca-
tion by their intervention. Accordingly, participants can
also be considered blinded.
Intervention
In the mentioned pilot study the overshadowing treat-
ment known from the paradigm of classical conditioning
was tested on pediatric cancer patients. To increase
efficiency and applicability, an overshadowing technique
known from Broberg and Bernstein will be used [34].
Implementing overshadowing in the hospital’s daily rou-
tine requires easy handling and regard to the high hy-
gienic standards on the oncology ward, although in the
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ent candy and the control group flavorless placebo tab-
lets instead of drinks. During three chemotherapy cycles
the experimental group will get their treatment (candy)
prior to each infusion. To avoid influences of possible
aversive taste reactions, the flavor of candy will be
changed from infusion to infusion.
Determining an evaluation period of three cycles can
be seen as a compromise. On the one hand, more cycles
may increase the intervention effect compared with the
placebo condition. On the other hand, more cycles also
increase the danger of withdrawals, missing data and
comparability of participants and their treatment as the
total number of treatment cycles differs widely between
low-risk Hodgkin lymphoma and Ewing sarcoma, for ex-
ample. Three cycles are thus a trade-off between a large
effect size and threatened data quality. The pilot study
[37] and the basic research [39] showed that even less
than three cycles – where each comprises several uncon-
ditioned stimulus–conditioned stimulus pairings – is
sufficient. However, to determine the applicability of the
intervention in daily clinical routine (the third subgoal),
the overshadowing treatment in the experimental group
will be continued until the end of treatment without any
further outcome assessment whenever possible.
Measures
Measuring nausea and vomiting
Symptoms of nausea and emesis will be measured using
discomfort logs administered by patients. These logs
have been successfully used in our pilot study [37].
They assess nausea and vomiting on 6-point Likert
scales focusing on intervals of 2 hours, thus leading to
12 ratings every day. Children from 4 to 7 years of age
will be interviewed by a blinded interviewer about their
symptoms, and also parents will be asked about their
observations. Children from the age of 8 years will use
a self-assessment version.
As a second measure, the combined nausea and
vomiting scale Baxter Retching Faces (BARF) by Baxter
and colleagues will be used [40]. BARF uses a 6-point vis-
ual analogue scale with six comic faces expressing mimics
ranging from neutral mood to vomiting. The authors de-
veloped the BARF scale for children aged from 4 to 17Table 4 Planned measurements for study aims and subgoals
Measurement Pre-chemothe
Nausea and vomiting (discomfort log, BARF)
Anxiety (KAT-II, STAI)
Quality of life (Kiddy-KINDL, Kid-KINDL, Kiddo-KINDL)
Adherence (caregivers and physicians questionnaires)
BARF, Baxter Retching Faces; KAT-II, Kinder-Angst-Test (Children Anxiety Test); KINDL
each age group); STAI, State and Trait Anxiety Inventory.years. The validation study confirms reliability and validity
among patients from 7 to 18 years old. In our study, the
BARF scale will be administered by all patients.
There will be two measurement points: the anticipa-
tory measurement phase prior to the third chemother-
apy cycle, and also the post-treatment phase after the
third chemotherapy cycle (see Figure 1 and Table 4).
Measuring anxiety
The Kinder-Angst-Test-II/Children Anxiety Test-II [41]
is a revision of the questionnaire for German-speaking
children and adolescents referring to the trait concept
developed in 1969. The trait scale for measuring the
anxiety disposition was kept and extended to aspects of
state anxiety and was normalized. The revised Kinder-
Angst-Test-II consists of three questionnaires, acquiring
two different aspects of anxiety. One questionnaire (Form
A) appraises trait anxiety, whereas the two others (Form P,
Form R) appraise the state anxiety, particularly the antici-
pated respectively reminded anxiety. The age range for ap-
plication reaches from 9 to 16 years.
Form A consists of 20 items. The questionnaires Form
P and Form R consist of 12 items each, with differences
to the referred time period. To operationalize state anx-
iety, questionnaire Form P will be used prior to the third
chemotherapy cycle (see Table 4).
The State and Trait Anxiety Inventory [42] is a self-
report inventory with 20 items each for trait and state
anxiety (two questionnaires). Items are rated on a four-
level scale, ranging from not at all to very, to measure
the intensity of anxiety. Adolescents older than 15 years
will be only asked to complete the state anxiety ques-
tionnaire. The state scale will be assessed prior to the
third chemotherapy cycle (see Table 4).
Measuring quality of life
The German Children's Quality of Life Questionnaire
(KINDL) – Revised is a quality-of-life questionnaire for
children with 24 items and allows assessments of six
domains: physical well-being, psychological well-being,
self-esteem, family, friends, and daily function [43]. Reli-
ability scores (Cronbach’s α = 0.85) and validity of the
instrument are confirmed [44]. There are three different





, German Children's Quality of Life Questionnaire (Kiddy/Kid/Kiddo version for
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age, Kid-KINDL for children aged from 8 to 12, Kiddo-
KINDL for adolescents aged from 13 to 16, Kiddy-KINDL
parent’s version for children aged from 4 to 7, and KINDL
parent’s version for children and adolescents aged from 8
to 16 years of age.
To assess quality of life, pediatric patients will complete
the KINDL-R versions after the third chemotherapy cycle
(see Table 4).
Measuring adherence
Adherent behavior will be obtained through ratings from
caregivers and physicians. As in the primary study, the
caregivers and physicians administer a questionnaire
with eight items to assess the adherent behavior of the
children and adolescents. Answers – for example, the in-
take of medicine – can be rated on a four-level scale
from poor to very good (poor, a little, good, very good).
The rating of patients’ adherent behavior will proceed
after the third chemotherapy cycle (see Table 4).
Statistical analysis
The effect of the overshadowing treatment on both an-
ticipatory (t1) and post-treatment nausea and vomiting,
anxiety, quality of life and adherence (t2) will be analyzed
using analysis of covariance comparing mean scores of
intervention and control group while controlling for dos-
age of antiemetics. To account for different appropriate ab-
solute dosages (mg/kg or mg/m2) among different patients
and drugs, the variable dosage will be operationalized as
the percentage of the recommended maximum dosage for
each patient and drug. The assumed dependence between
the prevalence of post-treatment (t2) and ANV (t1) will be
determined by Pearson correlation coefficient.
Discussion
Timetable
In consideration of the number of patients and the dis-
tribution of diagnoses in previous years, 23 patients per
year in the study clinic would meet the inclusion criteria.
Extrapolating this number leads to an inclusion period
of approximately 2.5 years. If the number of participants
is less than expected, the investigation will be extended
to include a second center (a verbal commitment from
University Clinic Lübeck was received). In that case the
randomization procedure will be repeated in the second
center. The trial is intended to start in summer 2013.
Limitations
Several limitations of this study have to be mentioned.
First, it is unclear whether it will be possible to produce
balanced study arms regarding diagnoses and anti-
emetics, respectively. In cases of clear imbalances, their
impact on the result has to be discussed. Second, it is anopen question whether overshadowing will work equally
independently of age. Additionally, it is unclear whether
ratings of ANV are influenced by the administering per-
son (self-rating vs. third-person rating). However, our
pilot study did not reveal any influence of age or appli-
cation mode. Third, a paradox conditioning might occur:
since nausea and vomiting are expected to occur closely
after the application of candy, the latter might be associ-
ated with nausea and vomiting. Hence, both might occur
as a consequence of other candy independently of treat-
ment situations. However, this will not influence the de-
sired effect on ANV as t1 lies before application of
candy in the context of the third treatment cycle. Unin-
tended induction of nausea and vomiting in patients’
everyday life is seen as unlikely since the tastes used as
scapegoats are rather rare.
Trial status
Ready to start recruitment.
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